New Drug Approvals

OCTOBER 12, 2024

ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. 2007 ; Kocis et al., 2016 ; Abushakra et al.,

Pharmacokinetics 62

Pharmacokinetics Small Molecule Disease Licensing 62

The Pharma Data

MARCH 30, 2021

(NASDAQ:AMGN) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a privately held biopharmaceutical company based in Seattle that develops small-molecule therapies designed to promote regeneration and repair of multiple tissues. About Rodeo Therapeutics.

Small Molecule 52

Small Molecule Therapies Disease Science 52

Drug Target Review

APRIL 19, 2024

And so, I have been the managerial co-founder and CEO of Sibylla since 2017. The discovery of the folding intermediate states to target has been enabled by our proprietary computational platform, and the development of small molecule folding interfering degraders is now accelerated by a proprietary AI platform.

Molecular Biology 111

Molecular Biology Research Pharmaceuticals Small Molecule 111

Elrig

APRIL 30, 2024

One aim of this work was to develop a set of tools to be later used in a high-throughput screen to identify small molecules for potential therapeutic uses as the current large molecule therapeutics do not show good selectivity. In August 2017, I joined Prof. Barnes at the University of Birmingham and Celentyx Ltd.,

Small Molecule 52

Small Molecule Doctors Pharmacy Disease 52

The Pharma Data

NOVEMBER 15, 2020

Urovant’s lead drug candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist being evaluated for the treatment of OAB, abdominal pain associated with irritable bowel syndrome (IBS) in men with OAB, and for men suffering from OAB with benign prostatic hyperplasia (BPH).

Science 52

Science Small Molecule FDA Approval Therapies 52

Drug Target Review

MAY 23, 2023

Micro- and macroalgae from both marine and fresh water produce small molecules and secondary metabolites with aggregative, anti-inflammatory, antioxidant, antimicrobial, anti-viral and anti-tumoural bioactivities. Examples include phlorotannins from brown seaweeds and small molecules like terpenoids and peptides, found in microalgae.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

JUNE 22, 2023

in December 2022 about changes to their initial 2017 partnership whereby Daiichi Sankyo obtained the Marketing Authorization for Yescarta ®. .–(BUSINESS WIRE)– Kite Pharma, Inc., to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc. This follows the announcement made by Daiichi Sankyo and Kite Pharma, Inc.

Therapies 40

Therapies Marketing Small Molecule Science 40

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

Practical Cheminformatics

OCTOBER 8, 2024

Testing Claude’s Molecule Generation Ability To test the molecule generation ability of Claude, a general-purpose LLM from Anthropic, I prompted it to generate analogs for hits from fragment screens. These fragment hits are small molecules with between 11 and 21 heavy atoms.

Fragment Screening 130

Fragment Screening Packaging Organic Chemistry Small Molecule 130

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. These evaluations include the active pharmaceutical ingredient (API), also known as the drug substance, and the drug product (formulated product).

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

New Drug Approvals

SEPTEMBER 13, 2024

21] In August 2017, it was announced that Cerecor had sold its rights to aticaprant to Janssen Pharmaceuticals. [22] 22] [21] Janssen was also experimenting with esketamine for the treatment of depression as of 2017. [21] Dhir A (January 2017). Jump up to: a b c Bushey R (August 2017). August 2017. nM vs. 24.0

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

The Pharma Data

MARCH 1, 2022

” The lead molecule, SDI-118, is a small molecule currently in Phase 1b studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

Metabolite Tales Blog

DECEMBER 13, 2023

Conjugation of small molecule drugs to glucuronic acid is catalysed by several UGTs to frequently form N – and O -glucuronides. As in this example, most N -glucuronides of small molecule drugs are innocuous and possess no pharmacological activity. J Pharm Biomed Anal. Sundararaghavan VL, Sindhwani P, Hinds TD Jr.

Small Molecule 59

Small Molecule Metabolic Stability Treatment Drugs 59

The Pharma Data

DECEMBER 15, 2020

Small Molecule Inhibitors. NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel. Oral, Small Molecules. KAN-101 is in a randomized, double-blind, placebo-controlled Phase I study, Assessment of KAN-101 in Celiac Disease.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

Creative Biolabs

JUNE 29, 2023

While the development of small molecule drugs targeting GPCRs, the development of monoclonal antibody drugs has also received great attention. Due to the relatively small extracellular domain of GPCR, complex signal activation, and the relatively large structure of traditional IgG antibodies, it is very difficult to develop.

Therapies 52

Therapies Small Molecule Drugs Drug Development 52

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. Smith joined SpringWorks at the company’s inception in 2017 and was a founding member of the management team.

Small Molecule 52

Small Molecule Engineering Clinical Development Pharmaceuticals 52

KIF1A

JUNE 30, 2023

Advancing Progress at the Chung Lab Wendy Chung, MD, PhD, and her team at Columbia University Medical Center in New York City have been our leading partners since the founding of KIF1A.ORG in 2017. In 2017, the Chung Lab launched the first and only global KIF1A Patient Registry and Natural History Study with funding from KIF1A.ORG.

Small Molecule 52

Small Molecule Treatment Doctors Research 52

The Pharma Data

DECEMBER 9, 2020

333-222268) previously filed with the Securities and Exchange Commission (the “SEC”) on December 22, 2017 and declared effective by the SEC on January 5, 2018. The shares of common stock are being offered by Oncternal pursuant to a “shelf” registration statement on Form S-3 (File No.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Treatment 52

The Pharma Data

JANUARY 4, 2021

SENS-401 has demonstrated highly encouraging efficacy in preclinical models and we are excited to progress this small molecule towards clinical trials to address this significant unmet medical need in cancer patients undergoing cisplatin treatment. 2017 Oct;38(9):1355-1361. D’heygere, R. Kuhweide, H. Source link.

Clinical Trials 40

Clinical Trials Small Molecule Therapies Treatment 40

NIH Director's Blog: Drug Development

JULY 20, 2017

Cystic Fibrosis Foundation News Release, July 18, 2017. Rommens JM1, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, et al. 1989 Sep 8;245(4922):1059-1065. Links : Positive Early Study Results for Next-Generation CFTR Modulators.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Disease 52

KIF1A

MAY 31, 2024

Advancing Research at the Chung Lab Recent Move to Boston Children’s Hospital Wendy Chung, MD, PhD, and her team have been our leading partners since the founding of KIF1A.ORG in 2017. In 2017, the Chung Lab launched the first and only global KIF1A Patient Registry and Natural History Study with funding from KIF1A.ORG.

Treatment 52

Treatment Small Molecule International Research 52

Alta Sciences

APRIL 17, 2024

The FDA approved the first gene therapy in 2017 for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL), and as of December 2023, there are over 30 approved cell and gene therapies on the market in the U.S.A.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Drug Target Review

MAY 31, 2024

Incredible advances in machine learning-driven tools allow us to predict the 3D structure of previously unsolved proteins, unlocking the power of structure-based drug design for drugging these targets, and most recently, the ability to predict protein assemblies, which contain both the protein and putative small molecule binders.

Organic Chemistry 45

Organic Chemistry Computational Chemistry Small Molecule Disease 45

The Pharma Data

NOVEMBER 8, 2020

In 2017 we bet on refocusing our strategy on medical dermatology to best address patients’ unmet needs. Several novel small molecule leads were the subject of this achievement. If the company chooses to exercise the option, Almirall plans to start a Phase III trial in CTCL in 2021 to secure launch as early as 2023.

Licensing 52

Licensing Licensing Marketing Production 52

The Pharma Data

NOVEMBER 5, 2020

Prior to that, Taveras was vice president of Small Molecule Drug Discovery and CMC Development at Biogen Idec, and Alantos Pharmaceuticals, which was acquired by Amgen in 2007. Prior to joining Navitor, Hughes served as president and CSO of Zafgen and previously led Zafgen as CEO from 2008 to 2017.

Analytical Chemistry 40

Analytical Chemistry Pharmaceuticals Small Molecule Therapies 40

The Pharma Data

SEPTEMBER 2, 2020

Fenebrutinib is designed to be a highly selective small molecule and is the only reversible (non-covalent) BTK inhibitor currently in Phase III development in MS. Characteristics and Patient Reported Outcomes of Patients Initiating Ocrelizumab in the NARCOMS Registry from 2017 to 2019.

Clinical Trials 52

Clinical Trials Treatment Disease Therapies 52

Agency IQ

FEBRUARY 23, 2024

Additionally, this approach is generally no longer applicable to new treatments that are more targeted in their effects, such as immunotherapies and targeted small molecule therapies. This workshop built on three prior workshops held by the FDA-AACR, which took place in 2015, 2016 and 2017.

Science 40

Science FDA Trials Clinical Pharmacology 40

NIH Director's Blog: Drug Discovery

APRIL 11, 2017

Researchers soon began screening a chemical library and its more than 380,000 traditional drug candidates to find the right small-molecule inhibitor, the preferred compound in drug discovery. Missing was the usual pocket-shaped active site, where a traditional small molecule can readily bind and block function.

Small Molecule 52

Small Molecule Science Drug Development Disease 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. 2017 ; Ilievski et al., Epub 2017 Nov 6 PubMed.

Small Molecule 62

Small Molecule DNA Disease Trials 62

LifeSciVC

APRIL 27, 2023

Fourteen years on, this corporate experiment has gone far beyond the initial idea, and has established an R&D engine more effective than most big pharma R&D groups at producing best-in-class small molecules against targets that matter in human disease biology. and swiveled her monitor to show me the news.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

The Pharma Data

NOVEMBER 29, 2020

” “The emergence of the PROTAC technology represents another breakthrough in the identification of small molecule drugs. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment. 2017, 16 , 101-114. Aguilar, A.; Bernard, D.;

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

MARCH 4, 2021

Under the 2017 collaboration agreement, Takeda received equity in Ovid and was eligible to receive up to $85 million in payments for regulatory milestones, including the initiation of Phase 3 clinical trials. Ovid’s most advanced pipeline programs include OV935 (soticlestat) in collaboration with Takeda and OV101 a ?-selective

Treatment 52

Treatment Clinical Trials Pharmaceutical Companies Trials 52

The Open Targets Blog

APRIL 5, 2023

The Druggable Genome The Druggable Genome is the subset of all human genes encoding proteins that could be targeted with a small molecule or antibody drug [4]. 2017 Apr 11;8(4):803-812. You need hundreds of millions of cells to screen the whole genome; to screen even just the druggable genome requires tens of millions of cells.

Small Molecule 52

Small Molecule Disease RNA Treatment 52

The Premier Consulting Blog

APRIL 25, 2023

In the US, new small molecule drugs are developed under the requirements of Sections 505(b)(1) and 505(b)(2) of the FFDCA. A 505(b)(2) NDA leverages information from studies in the literature and/or approved labeling for another drug that the sponsor does not own or have right of reference to.

FDA 52

FDA Animal Testing Pharmacokinetics Pharmaceuticals 52

Agency IQ

DECEMBER 11, 2023

Oncology at FDA in 2023: A quick glance at the numbers First created under the 21st Century Cures Act of 2016 and launched in 2017, FDA’s Oncology Center of Excellence (OCE ) “unites experts across the FDA to conduct expedited review of medical products for oncologic and hematologic malignancies.”

FDA 40

FDA Science Clinical Trials Trials 40

New Drug Approvals

JULY 10, 2023

Zavegepant is a highly soluble small molecule calcitonin gene related peptide (CGRP) receptor antagonist, with potential analgesic and immunomodulating activities. Also, according to a January 2017 study published in the journal Headache, an estimated 2.6 The clinical trial is expected to complete in September 2020.

Clinical Trials 40

Clinical Trials Treatment Trials FDA 40

Drug Target Review

OCTOBER 4, 2023

Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs. 56 , 733–737 (2017).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126